GeoWealth Management LLC Has $728,000 Stake in DexCom, Inc. (NASDAQ:DXCM)

GeoWealth Management LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 165.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,366 shares of the medical device company’s stock after buying an additional 5,836 shares during the period. GeoWealth Management LLC’s holdings in DexCom were worth $728,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Commerce Bank increased its position in shares of DexCom by 1.9% during the fourth quarter. Commerce Bank now owns 19,295 shares of the medical device company’s stock valued at $1,501,000 after purchasing an additional 361 shares during the period. Canada Pension Plan Investment Board raised its stake in shares of DexCom by 34.6% in the 4th quarter. Canada Pension Plan Investment Board now owns 766,566 shares of the medical device company’s stock valued at $59,616,000 after buying an additional 196,873 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of DexCom by 104.3% during the 4th quarter. Marshall Wace LLP now owns 539,295 shares of the medical device company’s stock worth $41,941,000 after acquiring an additional 275,295 shares during the period. NewEdge Advisors LLC boosted its position in shares of DexCom by 122.5% during the 4th quarter. NewEdge Advisors LLC now owns 23,905 shares of the medical device company’s stock valued at $1,859,000 after acquiring an additional 13,159 shares in the last quarter. Finally, United Capital Financial Advisors LLC raised its position in DexCom by 56.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 17,649 shares of the medical device company’s stock worth $1,373,000 after purchasing an additional 6,401 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 0.2 %

NASDAQ:DXCM opened at $68.59 on Monday. The stock has a market cap of $26.90 billion, a price-to-earnings ratio of 47.97, a PEG ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $74.98 and a two-hundred day moving average price of $76.75. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $139.24.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Cfra Research raised shares of DexCom to a “hold” rating in a report on Friday, March 21st. Mizuho assumed coverage on DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price on the stock. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.00.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 105,009 shares of company stock valued at $8,044,178. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.